- AU$15.80m
- AU$19.47m
Brief: Imugene Ltd Says Leslie Chong Resigns As CEO
Australia's Imugene loses most in over 8-years on discounted placement
Brief: Imugene To Raise A$11.12 Million Via Placement At A$0.095 Per Share
Brief: Imugene Requests Trading Halt Pending Proposed Capital Raising Announcement
Australia's Imugene surges after US FDA grants product Fast Track status
Brief: Imugene Ltd Says FDA Grants Fast Track Designation To Co's Azer-CEL For CLL/SLL And MZL
Brief: Imugene Launches A$12 Mln Placement At A$0.18 Per Share
Brief: Imugene Seeks Trading Halt Pending Proposed Capital Raising Announcement
Brief: Imugene Posts HY Net Loss Attributable A$37.8 Million
Brief: Imugene Signs Strategic Collaboration With JW Therapeutics
Australia's Imugene gains on alliance with JW Therapeutics for tumour treatment
Brief: Imugene Posts FY Net Loss Attributable A$69 Million
Australia's Imugene falls on discounted placement
Brief: Imugene Says Received Firm Commitments For A $22.5 Million Placement At A$0.33 Per Share
Brief: Imugene Seeks Trading Halted Pending An Announcement On Capital Raising
Brief: Imugene Says US Patent Allowance For Co's Oncarlytics
Brief: Imugene Says Cel Granted FDA Fast Track Designation In Blood Cancer DLBCL
Australia's Imugene climbs on FDA fast-track designation for lymphoma drug
Brief: Imugene Ltd Appoints Darren Keamy As CFO